Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL901672 | 0.89 | TAAR1 (0.53) | TAAR1FFAR1MRGPRX4NR3C2MAOB | |
| SCHEMBL11066194 | 0.87 | NPC1 (0.46) | TAAR1FFAR1ALOX5CNR1MEN1 | |
| SCHEMBL13237150 | 0.84 | VNN1 (0.47) | TAAR1MEN1KMT2AIDO1AGXT | |
| SCHEMBL7340106 | 0.84 | TAAR1 (0.57) | TAAR1FFAR1CNR1NR3C2 | |
| SCHEMBL27973686 | 0.83 | SPR (0.54) | TAAR1ALOX5OR51E2F2RL1 | |
| SCHEMBL11073323 | 0.83 | HCAR2 (0.49) | TAAR1FFAR1 | |
| SCHEMBL26343023 | 0.83 | FFAR1 (0.57) | TAAR1FFAR1CNR1NR3C2 | |
| SCHEMBL3944516 | 0.82 | MAOB (0.52) | MEN1KMT2AMRGPRX4MAOB | |
| SCHEMBL23901663 | 0.81 | IAPP (0.56) | TAAR1FFAR1CNR1NR3C2MAOB | |
| SCHEMBL755111 | 0.81 | F2RL1 (0.57) | FFAR1ALOX5OR51E2F2RL1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303493-A1 | ANTIBACTERIAL ADJUVANTS AND APPLICATIONS THEREOF | SAN JOSE STATE UNIVERSITY RESEARCH FOUNDATION | 2023-09-28 | — | — | US | disclosed |
| US-20030236302-A1 | Synthetic derivatives | SYNTA PHARMACEUTICALS CORP. | 2003-12-25 | — | — | US | disclosed |
| WO-2003072103-A1 | SYNTHETIC DERIVATIVES | KAVA PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303493-A1 | ANTIBACTERIAL ADJUVANTS AND APPLICATIONS THEREOF | CAPG, SLC11A2, CAPRIN1 | TAAR1 4154/4885FFAR1 2959/4885ALOX5 1472/4885 |
| US-20030236302-A1 | Synthetic derivatives | CBR1, CBR3, REL | TAAR1 435/4885FFAR1 583/4885ALOX5 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.